Reta-10mg
A reference-grade lyophilized material supplied for controlled laboratory and analytical applications.
Form: Lyophilized powder (10mg)
🔬 Retatrutide — Overview
Retatrutide (development name LY-3437943) is an investigational peptide-based therapeutic designed as a triple hormone receptor agonist acting on:
- Glucagon-like peptide-1 receptor (GLP-1R)
- Glucose-dependent insulinotropic polypeptide receptor (GIPR)
- Glucagon receptor (GCGR)
This triple agonism is intended to simultaneously modulate metabolic pathways involved in glycemic control, appetite regulation, energy balance, and weight loss, making Retatrutide a leading candidate in obesity and type 2 diabetes research and clinical trials. It remains experimental and not currently FDA-approved.
📌 Brief Functional Description
- Triple receptor agonist peptide: designed to activate GLP-1, GIP, and glucagon receptors to coordinate insulin secretion, appetite suppression, and metabolic regulation.
- Clinical research focus: obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and related cardiometabolic endpoints.
🧪 Chemical & Structural Information
🔢 CAS Number
- 2381089-83-2 — the registered CAS for Retatrutide.
🧬 Molecular Formula
- C221H342N46O68 — the elemental composition of the peptide backbone with modifications.
⚖️ Molecular Weight
- ≈4,731 g/mol (average) — approximate molecular mass of Retatrutide.
🧬 Structure & Sequence Features
Retatrutide is a synthetic peptide with engineered amino-acid substitutions and lipid/side-chain modifications to optimize receptor binding and pharmacokinetics. Its sequence includes modified residues to improve stability and potency across all three targeted receptors.
A simplified representation (one-letter fragments) reflects peptide backbone motifs tailored to GLP-1, GIP, and glucagon receptor engagement, though the full structure is long and complex.
🧠 Mechanism & Research Context
- Triple agonism: Retatrutide engages GLP-1, GIP, and glucagon receptors, linking incretin signaling with glucagon pathways to effect weight loss and glycemic improvements more robustly than single or dual agonists.
- The additional glucagon receptor activity is hypothesized to enhance energy expenditure and fat metabolism beyond what dual GLP-1/GIP compounds deliver.
⚠️ Safety & Regulatory Notes
- Retatrutide is still investigational and not approved by regulatory bodies like the FDA for general use; it remains in Phase 2/3 clinical trials.
🧪 Quick Reference
Property
Detail
Name
Retatrutide (LY-3437943)
CAS #
2381089-83-2
Molecular Formula
C221H342N46O68
Molecular Weight
~4,731 Da
Type
Synthetic modified peptide triple agonist
Mechanism
GLP-1, GIP, and glucagon receptor agonist
Research Use
Obesity, diabetes, metabolic disease clinical trials
| Property | Detail |
|---|---|
| Name | Retatrutide (LY-3437943) |
| CAS # | 2381089-83-2 |
| Molecular Formula | C221H342N46O68 |
| Molecular Weight | ~4,731 Da |
| Type | Synthetic modified peptide triple agonist |
| Mechanism | GLP-1, GIP, and glucagon receptor agonist |
| Research Use | Obesity, diabetes, metabolic disease clinical trials |
Notice: For Research Use Only. Not for human or veterinary use